Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.
The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.
The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.
Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.
Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.
Price: 15.48, Change: +0.40, Percent Change: +2.63
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。